



UNITED STATES  
NUCLEAR REGULATORY COMMISSION

REGION IV

611 RYAN PLAZA DRIVE, SUITE 400  
ARLINGTON, TEXAS 76011-8064

MAR 8 1994

Docket: 030-14786  
License: 35-18284-01

Logan Hospital and Medical Center  
ATTN: Roland Gee, Administrator  
P.O. Box 1017  
Guthrie, Oklahoma 73044

SUBJECT: NRC INSPECTION REPORT 030-14786/93-01

Thank you for your letter of February 18, 1994, in response to our letter and Notice of Violation dated January 11, 1994. We have reviewed your reply and find it responsive to the concerns raised in our Notice of Violation. We will review the implementation of your corrective actions during a future inspection to determine that full compliance has been achieved and will be maintained.

Sincerely,

*Charles L. Cain*

Charles L. Cain, Chief  
Nuclear Materials Inspection Branch

cc:  
Oklahoma Radiation Control Program Director

9403140052 940308  
PDR ADOCK 03014786  
C PDR

*JEET 11*

bcc w/copy of licensee's letter:  
DMB - Original (IE-07)  
LJCallan  
SLCollins  
LWCamper  
RAScarano, DRSS/RIV  
MMessier, OC/LFDCB (4503)  
WLFisher  
CLCain  
GLGuerra  
NMIB  
MIS System  
RIV Files (2)

RIV:NMIB <i>GLG</i>	C:NMIB <i>CLC</i>			
GLGuerra	CLCain			
03/7/94	03/8/94			

Logan Hospital and  
Medical Center

-2-

bcc w/copy of licensee's letter:

DMB - Original (IE-07)

LJCallan

SLCollins

LWCamper

RAScarano, DRSS/RIV

MMessier, OC/LFDCB (4503)

WLFisher

CLCain

GLGuerra

NMIB

MIS System

RIV Files (2)

RIV:NMIB <i>GLG</i>	C:NMIB <i>HC</i>			
GLGuerra	CLCain			
03/7 /94	03/8 /94			

February 18, 1994

FEB 22 1994

U.S. Nuclear Regulatory Commission  
Attn: Document Control Desk  
Washington, D.C. 20555

Re: **Reply to a Notice of Violation**

Gentlemen:

This letter is a response to the "Notice of Violation, NRC Inspection Report 030-14786193-01.

1) Reason for the violation:

The administration of fifty (50) microcuries of Sodium Iodide I-131 was administered on the verbal order of Dr. Massad. It was an oversight on our part that a written directive was not prepared. This was our first and only dosage of I-131 above 30 microcuries and it was soon after the new regulations took effect.

2) Corrective steps taken:

The event was recognized during our quarterly review of the Quality Management Program and was brought to the attention of the users in the Radiation Safety Meeting held May 21, 1992, the same day as the review. At that time the requirements and the Quality Management Program were reviewed by the users with Dr. Ficken, physicist. The need for written directives for any dosage of I-131 above 30 microcuries was stressed and understood.

3) Corrective steps taken to avoid further violations:

I-123 will be used for future thyroid uptake/scans and I-131 will be avoided unless specifically ordered in writing by the licensed user. We will utilize our "Written Directive Form" to document the I-131 usage and will keep a file for review in the Director's office. The Quality Management Program is reviewed each quarter to assure compliance. We have no repeat violations since April 7, 1992.

~~94030/0271~~

94-0543


U.S. Nuclear Regulatory Commission  
Page 2  
February 18, 1994

4) Date when full compliance will be achieved:

Full compliance has been achieved since May 21, 1992. All users are aware of the violation and understand the requirements for written directives.

I trust that this response answers the violations sited. Please contact me if I can be of further assistance.

Sincerely,



Roland D. Gee  
Administrator

RDG:ab

cc: U.S. Nuclear Regulatory Commission  
Regional Administration, Region IV  
Arlington, TX 76011